A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
Trial details
- Registry ID
- NCT07464145
- Drugs studied
- NDV-01 (sustained-release gemcitabine-docetaxel)
TrialRedline tracks 6 clinical trials sponsored by Relmada Therapeutics, Inc.: 4 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerNCT07464145 | NDV-01 (sustained-release gemcitabine-docetaxel) | Not yet recruiting | 2029-12Estimated |
| Safety of REL-1017 for Major Depressive DisorderNCT04855760 | REL-1017 | Completed | 2023-07-27Actual |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04688164 | REL-1017 | Completed | 2022-11-01Actual |
| A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)NCT05081167 | REL-1017 | Completed | 2022-09-13Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBCNCT06663137 | NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Recruiting | 2027-11Estimated |
| Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDNCT03051256 | REL-1017 | Completed | 2019-07-30Actual |
Names as written in the registry records.
NCT06663137 · Relmada Therapeutics, Inc.
Before: Aug 2025. After: Nov 2027.
NCT07464145 · Relmada Therapeutics, Inc.
Before: Sep 2029. After: Dec 2029.